MyFinsight
Home
Blog
About
Marketable securities
$50,615,164
Cash and cash
equivalents
$24,652,086
(61.68%↑ Y/Y)
Prepaid expenses and
other current assets
$4,365,267
(2086.84%↑ Y/Y)
Restricted cash
$100,000
(0.00%↑ Y/Y)
Total current assets
$79,732,517
(412.83%↑ Y/Y)
Goodwill
$14,869,399
(0.00%↑ Y/Y)
Deferred offering costs
$487,029
Total assets
$95,088,945
(212.59%↑ Y/Y)
Accumulated deficit
-$796,737,839
(-98.00%↓ Y/Y)
Total liabilities,
redeemable preferred stock...
$95,088,945
(212.59%↑ Y/Y)
Total stockholders'
deficit
-$213,300,623
(-564.30%↓ Y/Y)
Additional paid-in capital
$583,432,493
(57.57%↑ Y/Y)
Common stock 0.0001 par
value 250,000,000...
$4,723
(575.68%↑ Y/Y)
Total liabilities
$296,648,246
(374.42%↑ Y/Y)
Series a convertible
preferred stock 0.0001 par...
$11,741,322
Warrant liability
$232,690,185
Liability related to the
sale of future...
$60,000,000
(0.00%↑ Y/Y)
Total current
liabilities
$3,958,061
(56.52%↑ Y/Y)
Accrued expenses and
other current...
$2,510,505
(53.82%↑ Y/Y)
Accounts payable
$1,447,556
(61.41%↑ Y/Y)
Back
Back
Balance Sheet
Minerva Neurosciences, Inc. (NERV)
Minerva Neurosciences, Inc. (NERV)
source: myfinsight.com